Clinical and pathologic comparison among the 3 subtypes
Parameters for comparison . | CD94+ N = 10 . | CD94− N = 9 . | Mixed NK/T N = 6 . | P* . |
|---|---|---|---|---|
| Sex, male-female ratio | 8:2 | 8:1 | 2:4 | .047 |
| Median age, y | 43 | 57 | 26 | < 0.001 |
| Nuclear grade I:II:III | 6:1:3 | 1:5:3 | 3:1:2 | .42 |
| Clear-cell change | 3 | 3 | 0 | .31 |
| Angiocentric necrosis | 6 | 4 | 2 | .59 |
| Reactive infiltrates | 3 | 0 | 1 | .22 |
| CD56+ | 5 | 5 | 2 | .72 |
| Early stage I | 7 | 7 | 5 | .78 |
| Median WBC, 103/μL | 4.4 | 7.2 | 5.7 | .83 |
| Median HB, g/dL | 12.7 | 12.1 | 12.8 | .83 |
| Median PLT, 103/μL | 205 | 263 | 276 | .51 |
| Median LDH, U/L | 413 | 660 | 461 | .45 |
| Progression free | 7 | 1 | 3 | .031 |
| Survival longer than 1 y | 8 | 2 | 4 | .031 |
| Hemophagocytic syndrome | 2 | 0 | 0 | .21 |
Parameters for comparison . | CD94+ N = 10 . | CD94− N = 9 . | Mixed NK/T N = 6 . | P* . |
|---|---|---|---|---|
| Sex, male-female ratio | 8:2 | 8:1 | 2:4 | .047 |
| Median age, y | 43 | 57 | 26 | < 0.001 |
| Nuclear grade I:II:III | 6:1:3 | 1:5:3 | 3:1:2 | .42 |
| Clear-cell change | 3 | 3 | 0 | .31 |
| Angiocentric necrosis | 6 | 4 | 2 | .59 |
| Reactive infiltrates | 3 | 0 | 1 | .22 |
| CD56+ | 5 | 5 | 2 | .72 |
| Early stage I | 7 | 7 | 5 | .78 |
| Median WBC, 103/μL | 4.4 | 7.2 | 5.7 | .83 |
| Median HB, g/dL | 12.7 | 12.1 | 12.8 | .83 |
| Median PLT, 103/μL | 205 | 263 | 276 | .51 |
| Median LDH, U/L | 413 | 660 | 461 | .45 |
| Progression free | 7 | 1 | 3 | .031 |
| Survival longer than 1 y | 8 | 2 | 4 | .031 |
| Hemophagocytic syndrome | 2 | 0 | 0 | .21 |
P was determined by analysis of variance (ANOVA).